Regeneron stock increased by 19% over the past month, driven by strong third-quarter earnings. But is Gilead the better pick?

Now, it’s worth noting Stock Advisor’s total average return is 1,062% — a market-crushing outperformance compared to 194 % ...

Drugs approved by the FDA’s expanding program to expedite reviews for products in line with the Trump administration’s agenda ...